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A retrospective study and survival analysis on bitches with mammary tumors 1 
spayed at the same time of mastectomy 2 
 3 
Spaying bitches with mammary tumors 4 
 5 
ABSTRACT  6 
The aim of the present study was to retrospectively assess whether spaying at the same time of 7 
mastectomy increased disease-free survival (DFS) in bitches with mammary tumors and to 8 
investigate the utility of clinical data when designing a surgical plan that includes gonadectomy.  9 
Data from 225 bitches were retrieved. Only 116 were surgically treated. Among these, 52 bitches 10 
underwent mastectomy and ovariectomy and 46 bitches underwent mastectomy alone. Survival 11 
analysis by Kaplan-Meier and in-between groups comparisons using Student’s T, Chi-square, and 12 
one-way ANOVA tests were performed. Eighteen bitches were already spayed. DFS was longer for 13 
bitches that underwent ovariectomy and mastectomy compared to those that were left intact 14 
(P=0.00064) or were already spayed (P=0.0098). Spaying status affected the tumor size (spayed: 15 
2.75 cm±2.72; intact: 1.76 cm±2.04; P=0.039), but not malignancy (P>0.05). Differences in age 16 
were detected between animals with benign and malignant tumors (9.1±2.8 and 10±2.3; P=0.004), 17 
with multiple and single tumors (10.18±2.6 and 9.3±2.8; P=0.007), and between purebred and 18 
mixed breed bitches (10.46 years ±1.78 and 9.27 years ±2.68; P = 0.005). Malignant tumors were 19 
larger than benign ones (2.17 years ±2.31 and 1.34 years ±1.82; P = 0.005) and size increased 20 
according to the degree of malignancy. DFS was shorter for animals presenting tumors >2 cm in 21 
size (P<0.006) and with tumors in the first pair of thoracic mammary glands (P=0.00009).  22 
Gonadectomy should be suggested to owners of intact bitches carrying mammary tumors and age, 23 
size of the tumor, and location should be carefully considered when performing surgery.  24 
 25 
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1. INTRODUCTION 28 
Canine mammary tumors (CMTs) are the most common reproductive neoplastic disease in dogs 29 
and, generally, the most reported tumor in intact bitches1. Surgery is the standard treatment, with 30 
good prognosis in animals with benign-to-low grade non metastatic tumors.  31 
The role of ovarian steroids on carcinogenesis of the mammary gland has been the object of several 32 
studies in bitches. Sexual steroids act both under physiological and pathological conditions due to 33 
the presence of hormone receptors in mammary tissue2-4, and they may have an autocrine/paracrine 34 
role in the growth of mammary tumors and in the maintenance of the disease5. Ductal growth is 35 
promoted by estrogens, whereas progesterone causes development and hyperplasia of lobulo-36 
alveolar tissue6. Progesterone might be involved in the upregulation of growth hormone (GH) 37 
production within the mammary tissue, leading to proliferation of mammary stem cells that could 38 
have a primary role in carcinogenesis 1, 7. Hormonal stimulation of mammary tissue occurs at every 39 
estrous cycle, so that the reduction of risk of mammary cancer development has been calculated in 40 
relation to age (i.e., number of estrous cycles) at gonadal removal 8-10. A systematic review of the 41 
literature on the effect of spaying on the risk of benign and malignant mammary tumors in the 42 
canine species, concluded that scientific evidence is too weak to serve as a basis for firm 43 
recommendation of spaying as a preventive measure11. Nevertheless, epidemiological studies 44 
suggest that in countries where dogs are routinely spayed at an early age, the incidence of mammary 45 
neoplasms is lower (e.g., United States) when compared to countries where spaying is not routinely 46 
performed (e.g., Norway)12, 13. On the other hand, associations between gonadectomy and other 47 
pathological conditions, such as urinary incontinence, cranial cruciate ligament rupture, hip 48 
dysplasia, osteosarcoma, and hemangiosarcoma have been recognized14. Hormonal deprivation 49 
following gonadal removal has also an impact on future health and longevity15. Therefore, surgical 50 
spaying of young healthy bitches should be performed based on a patient-specific approach, 51 
considering breed, age, surgical risk, and behavioral characteristics of the animal16.  52 
Gonadectomy has also been suggested as an adjuvant treatment to mastectomy: bitches with benign 53 
mammary tumors and hyperplastic lesions that underwent both mastectomy and gonadal removal at 54 
the same time, were seen to have a 50% decrease in recurrence of disease17, whereas bitches with 55 
mammary carcinomas variably responded to neutering at the time of mastectomy6.  56 
As literature data are not univocal and seem to suggest that gonadal removal in association with 57 
mastectomy can be beneficial mainly when hormone receptors are expressed by tumors, it would be 58 
very useful to re-evaluate this observation that is crucial for a clinician when suggesting the best 59 
treatment option for a patient.  60 
Some history data, such as the reproductive condition, and some clinically assessable factors, such 61 
as age, tumor size and tumor number, have been described for risk of CMTs development and for 62 
their value in predicting malignancy. CMTs are typically diagnosed in older animals and the median 63 
age of occurrence ranges from 8 to 10 years18-20. A correlation exists between tumor size and 64 
malignancy, with larger masses having higher risk of malignancy18, 21. On the contrary, the presence 65 
of multiple tumors does not necessarily indicate a high degree of malignancy or a bad prognosis, 66 
because each neoplasm can belong to a different subtype21, 22. 67 
This study is a retrospective investigation aiming to assess whether spaying at the time of 68 
mastectomy should be suggested to owners based on parameters collected in the contest of the 69 
clinical examination and on the analysis of disease-free survival.    70 
2. MATERIALS AND METHODS 71 
2.1 Data collection 72 
The database of the *** was searched for records of bitches that had been presented because of 73 
CMTs and that underwent mastectomy between January 2011 and January 2020. Each dog was 74 
counted only once, irrespective of the number of visits, and records were evaluated retrospectively. 75 
Only bitches with no previous history of mammary tumor were included. Data from animals that 76 
did not undergo surgery were included only in the descriptive analysis. Proper informed consent 77 
had been signed by the owners prior to surgery, allowing for surgical treatment and data collection 78 
for research purposes.  79 
Age, breed and spaying status of the patients, previous hormonal treatments, previous pregnancies, 80 
pseudo-pregnancies, previous reproductive conditions, clinical tumor features (number, location, 81 
and size), and evaluation of regional lymph nodes were retrieved from the records. 82 
The database contained also the standard pre-surgical diagnostics, such as blood exams, thoracic 83 
radiographies, cardiological assessment and, in some cases, abdominal ultrasounds and cytologic 84 
exams. All these preliminary exams had led to the decision of performing surgery. 85 
Surgery type, either mastectomy alone or mastectomy and gonadectomy (ovariectomy or 86 
ovariohysterectomy) had been recorded, together with the surgical approach for mastectomy and the 87 
histological diagnosis. Histological classification and grading were based on criteria defined by 88 
Zappulli (2019) and Peña (2019). 89 
Follow-up data were obtained by the clinical records or by contacting the owners for a check-up 90 
clinical examination at >365 days from surgery.  91 
2.2 Analysis of data  92 
Descriptive statistics was carried out considering data extracted from all retrieved clinical records 93 
and data are presented as mean and standard deviation (SD) for continuous parameters or as 94 
frequency for categories. Normality for continuous parameters was assessed by Shapiro-Wilk test.  95 
Survival analysis was carried out using Kaplan-Meier method with log-rank tests and Bonferroni’s 96 
post hoc test to estimate differences in disease-free survival (DFS) among spayed bitches, intact 97 
bitches that were subjected to mastectomy alone, and bitches that underwent mastectomy and 98 
gonadectomy at the same time. Only bitches that underwent surgery and had the surgically excised 99 
mammary tumor histologically evaluated were included. The same analysis was carried out to 100 
estimate differences in disease-free survival (DFS) according to tumor size, malignancy, and tumor 101 
location. Tumor size was considered as continuous; however, data were grouped in five categories 102 
for the survival analysis (A < 1 cm, B = 1 to <2 cm, C = 2 to <3 cm, D = 3 to <5 cm, E > 5 cm)10, 21. 103 
Disease-free survival (DFS) was calculated from the time of surgery to the time of diagnosis of a 104 
new mammary tumor. Bitches lost to follow-up and animals that died or that were euthanized for 105 
causes unrelated to mammary tumors were censored at the time of death. Animals lost to follow-up 106 
were censored at the time of their last contact with the clinician. 107 
Student’s T test for continuous normally distributed variables, Chi-square test, and one-way 108 
ANOVA followed by Bonferroni’s post hoc test for categories, were used to point out differences 109 
based on age, breed, spaying status, tumor size, and malignancy of tumors in bitches that underwent 110 
surgery. 111 
Significance was considered for P < 0.05. Statistical analyses were performed with the software R 112 
version 3.2.2. 113 
3. RESULTS 114 
Two-hundred and twenty-five bitches with a total number of 489 tumors were retrieved from the 115 
database. Characteristics of the animals (age, purebred or mixed breed, and spaying status) and 116 
characteristics of the tumors (size, number, location) are reported in Table 1 and in Table 2. The 117 
frequency of the different breeds is reported in Supplementary material (S1).  118 
None of the included bitches had ever received any hormonal treatment during its lifetime or had 119 
ever presented with any reproductive disease, according to information reported by owners. 120 
Nevertheless, eight bitches had previous pregnancies (0.03%, five bitches had one previous 121 
pregnancy, whereas three bitches had two previous pregnancies) and three bitches had previous 122 
pseudo-pregnancies (0.01%). At clinical examination, 13 bitches (5.8%) presented altered regional 123 
lymph nodes. Cytology was performed and they were included in the study only when the node was 124 
not metastatic. Nine of these patients were deemed as node-positive after histology (69.2%), 125 
whereas two of them presented just lymphadenitis (30.8%). The number of bitches that underwent 126 
mastectomy and that were diagnosed with CMTs based on the histological examination was 116, 127 
carrying a total number of 298 tumors. Frequencies of benign and malignant tumors are reported in 128 
Table 3. Surgical margins were clear in all the bitches according to histological examination. 129 
Histological types are reported in Table 4. 130 
Tumor removal was carried out with different approaches, more frequently with a regional 131 
mastectomy or with a combination of different techniques (i.e., regional mastectomy and simple 132 
mastectomy), when tumors were present on both sides (Table 5). 133 
Only 15.6% of the bitches that underwent surgery (n = 18) was already spayed and the 134 
gonadectomy happened at least two years before mammary tumors occurrence. Fifty-two out of 98 135 
intact bitches were spayed at the same time of mastectomy. Survival analysis showed a statistically 136 
significant difference in DFS depending on spaying status (P = 0.0007). Specifically, bitches that 137 
were subjected to spaying at the time of mastectomy showed longer DFS when compared with both 138 
bitches that were already spayed (P = 0.0098) and bitches that remained intact (P = 0.00064). 139 
However, median DFS for bitches that were subjected to spaying at the time of mastectomy was not 140 
available because recurrence was < 50% in both intact bitches and bitches that were spayed at the 141 
time of mastectomy (n = 9/64, 14% and n = 2/52, 3%, respectively). Recurrence in bitches that were 142 
already spayed was 27.8% (n = 5/18) and their median DFS was 757 days (95% CI, 369-1026).  143 
Statistically significant differences in mean age were detected between animals with benign and 144 
malignant tumors, as shown in Table 6. Animals with multiple neoplasms were older than the ones 145 
with single tumors (10.18 ± SD 2.6 and 9.3 ± SD 2.8, respectively), with statistically significant 146 
results (P = 0.004).  147 
 148 
No differences between the incidence of benign and malignant tumors between purebred and mixed 149 
breed animals were detected (P > 0.05), although purebred bitches had the tendency to develop 150 
mammary tumors at a younger age (mean 10.46 years ± SD 1.78) if compared to mixed breed ones 151 
(mean 9.27 years ± SD 2.68; P = 0.005).  152 
Being already spayed did not affect the frequency of benign and malignant tumors (P > 0.05), nor 153 
the degree of malignancy, I, II, or III (P > 0.05). However, intact bitches had smaller tumors when 154 
compared to spayed ones (mean 1.76 cm, ± SD 2.04 and 2.75 cm ± SD 2.72, respectively; 155 
P=0.003), although they showed a higher tendency to multiple tumors (P = 0.039). 156 
Tumor size was statistically different between benign and malignant neoplasms (Table 5) and	157 
differences in size were also detected based on the tumor grade, with grade III tumors being larger 158 
than grades I and II (P = 0.05 and P = 0.003, respectively). Grade I malignant tumors had a mean 159 
size of 2.1 cm (± SD 2.3), grade II malignant tumors had a mean size of 1.64 cm (± SD 1.1), and 160 
grade III malignant tumors had a mean size of 3.6 cm (± SD 2.2).  161 
Survival analysis showed a statistically significant difference in DFS depending on the size of 162 
mammary tumors (P = 0.003), considering the five classes mentioned in subsection 2.2. 163 
Specifically, smaller tumors belonging to classes A and B had a longer DFS when compared to 164 
larger tumors belonging to class E (P = 0.002 and P = 0.006, respectively; A: median DFS 2102 165 
days, 95% CI 1143-2385; B: median DFS 1148 days, 95% CI 1076-2267; D: median DFS 669 days, 166 
95% CI 434-669; E: median DFS 359, 95% CI 72-811). Class C included a low number of data, that 167 
were insufficient to the purpose of Kaplan-Meier analysis.  168 
Survival analysis showed also a statistically significant difference in DFS depending on location of 169 
mammary tumors (P = 0.00009). Animals presenting with neoplasms located in the cranial thoracic 170 
mammary glands (I pair), had a worse prognosis for mammary tumors recurrence (I: median DFS 171 
434 days, 95% CI 188-434; II: median DFS 1143 days, 95% CI 659-1143; III: median DFS 1502 CI 172 
811-2385; IV: median DFS 1259 days, 95% CI 1096-2385; V: median DFS 1148, 95% CI 759-173 
2385). No differences in DFS were detected between bitches presenting with single and multiple 174 
tumors (P > 0.05).  175 
4. DISCUSSION  176 
The effect on time free of disease of OHE at the same time of mastectomy was evaluated in a mixed 177 
population of bitches affected by mammary tumors at different stages. The population included in 178 
the present study shared some common characteristics to those included in previous studies in terms 179 
of age, breed, spaying status, and mean size of benign and malignant tumors18-21, 25 and additional 180 
factors such as location and number of tumors were assessed. The typical presentation for the 181 
diagnosis of canine mammary tumor is middle-aged non-spayed purebred bitches, however younger 182 
and mixed breed animals can be affected.  183 
Spaying status effect on canine mammary tumors has been widely investigated, with contradictory 184 
results11. It is commonly known that spaying before the first estrus comes with a lower risk of 185 
mammary tumors development8, and this confirms the involvement of ovarian steroids in mammary 186 
tissue carcinogenesis. Accordingly, our data showed that the number of spayed bitches presenting 187 
with CMTs was consistently lower than the number of intact ones. However, this might be also the 188 
consequence of a smaller general population of spayed animals in Italy, compared to the one of 189 
intact bitches. There is no data in the literature about the population of ovariectomized bitches, 190 
although spaying is a rather diffuse practice in Italy. Nevertheless, early spaying is becoming less 191 
popular when balancing benefits and possible adverse effects. 192 
Some owners decided upon mastectomy alone, notwithstanding the fact that gonadectomy was 193 
always recommended to owners of intact bitches presenting with CMTs, when overall clinical 194 
conditions made it advisable. The recommendation was based on the higher risk of uterine and 195 
ovarian disease in middle-aged and old bitches26 and on the higher risk of new malignant CMTs in 196 
bitches with a previous history of malignant CMT27. The reasons underneath this increased risk of 197 
CMTs might be well explained by the hormonal effect to which the whole mammary tissue is 198 
exposed to1. Furthermore, the positive effect of gonadectomy at the time of mastectomy as an 199 
adjuvant therapy has been investigated, with encouraging results especially on 200 
hyperplastic/dysplastic and benign mammary diseases17 and bitches with grade II carcinomas 201 
presenting estrogen receptors or with increased peri-surgical serum concentrations of 17β-estradiol6. 202 
However, to classify a tumor as hormonally dependent, receptors for sexual steroids need to be 203 
detected on neoplastic tissue. Some authors relate a decrease in receptors for ovarian steroids with a 204 
worse prognosis28, 29. Therefore, including the search of receptors for both estrogens and 205 
progesterone in post-surgical investigations in intact bitches, could represent a very useful tool to 206 
improve prognostic precision and treatment protocols1. 207 
The observation on hormone receptors in the removed tumors could not be included because it was 208 
not available in the database, and this represents an important limitation. However, when the 209 
clinician suggests a treatment option, he cannot rely on this information and focuses on general 210 
findings only. Results on DFS and rate of recurrence of CMTs in bitches that were spayed at the 211 
time of mastectomy were encouraging. Patients that remained intact had higher recurrence of 212 
CMTs. The fact that recurrence was even higher in already spayed bitches should be furtherly 213 
investigated in order to point out factors influencing mammary tissue carcinogenesis in the absence 214 
of hormonal stimulation. In addition, our results agree with those of Burrai et al. (2020), showing 215 
that spaying status had no significant influence on whether tumors were benign or malignant. The 216 
limited number of spayed bitches included does not allow us to consider malignancy responsible for 217 
higher recurrence rates in spayed bitches.  218 
The decisional process of the clinician should start with a complete evaluation of the patient, in 219 
order to assess its suitability for mastectomy and to decide the appropriate surgical technique and 220 
whether to include gonadectomy in its surgical plan. Patients presenting with mammary tumors 221 
should be carefully checked for evidence of metastatic disease30, starting with the evaluation of 222 
regional lymph nodes. These organs are difficult to assess when normal, and the easily palpable 223 
ones should be checked, possibly indicating regional metastasis1, 31, to be confirmed through 224 
cytological examination. There is evidence that disease-free survival is shorter and survival rate is 225 
lower in node positive patients32. Other clinical parameters are related to malignancy and prognosis. 226 
Age is a risk factor for neoplastic disease in general33, and the median age of occurrence of CMTs 227 
ranges from 8 to 10 years18-20, in accordance with our results, that also agree on the fact that median 228 
age of bitches with benign tumors is lower than age of animals with malignant ones21.  229 
Incidence of CMTs in purebred animals was higher than in mixed breed bitches and frequencies are 230 
coherent with information reported in studies that indicate a higher risk of CMTs in breeds such as 231 
Poodles, English Springer Spaniels, Brittany Spaniels, German Shepherds, Maltese terries, 232 
Yorkshire Terriers, Dachshunds, Doberman Pinschers, Leonbergers, and Boxers1, 34-35. However, 233 
few studies investigate the genetic predisposition of specific breeds towards mammary subtypes36, 37 234 
and further studies should be conducted.  235 
Majority of patients carried multiple nodules and had malignant neoplasms, although a lower degree 236 
of malignancy was more common than higher ones. In general, older animals have the tendency to 237 
carry multiple nodules and are expected to be diagnosed with malignant neoplasms. The presence of 238 
multiple nodules does not necessarily indicate a high degree of malignancy or a bad prognosis, 239 
because each neoplasm can belong to a different subtype21, 22. 240 
Some studies indicate that tumor location is not associated with tumor type38 nor with survival 241 
time38, whereas a more recent paper39 indicates tumor location as predictive of malignancy, with a 242 
significantly higher proportion of malignant tumors developing in the inguinal mammary glands. 243 
We found that incidence of nodules progressively increased from cranial to caudal mammary 244 
glands, probably because caudal abdominal and inguinal mammary glands physiologically have 245 
more abundant parenchyma40. In contrast with Ariyarathna et al. (2018), no difference in 246 
malignancy occurred according to tumor location, although a lower DFS was pointed out for bitches 247 
presented with nodules located in the first thoracic pair of mammary glands. This should be kept in 248 
mind by the surgeon, because more invasive surgery could be considered in these cases, although 249 
prospective studies correlating surgical techniques with tumor location represent an area for further 250 
research.  251 
In accordance with other studies18-19, 21, size of the tumor is another important clinical parameter 252 
with prognostic value, with malignant tumors being generally larger than benign ones. Our results 253 
show that among malignant tumors, larger size corresponds to higher malignancy grade and lower 254 
DFS.  255 
We conclude that spaying at the time of mastectomy should always be considered in intact bitches 256 
with mammary tumors, possibly followed by the additional assessment of hormone receptors 257 
presence on the removed tumors. Intact bitches around 9 years old, have higher probability to 258 
develop mammary tumors and older age of bitches and tumors size larger than 2 cm are more 259 
commonly related to malignant neoplasms. Location should be carefully considered when designing 260 
the surgical plan, because bitches with nodules located in the cranial thoracic mammary glands have 261 
a shorter time free of mammary tumors. This will help the clinician to make a more precise 262 
prognosis to the patient. 263 
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Table 4. Histological diagnosis (number: n and percentage: %) 
 n Percentage (%) 
Simple benign tumors   
   Adenoma, simple 32 10.7 
 
Ductal-associated benign tumors   
   Intraductal papillary adenoma 26 8.9 
   
Nonsimple benign tumors   
   Complex adenoma 10 3.4 
Table 1. Frequencies of some parameters of bitches with CMTs (n = 225) and tumors (n = 489). 
 Spaying status Breed Number of tumors† Location of tumors 





I II III IV V 
n 141 31 53 145 80 78 147 22 56 104 143 164 
Percentage 
(%) 62.7 13.8 23.5 64.4 35.5 34.7 65.3 4.4 11.5 21.3 29.2 33.6 
†Bitches with single or multiple neoplasms. 
Table 2. Mean and standard deviation (SD) of age of the bitches included in the study (n = 225) 
and size of the tumors.  
 Mean ±SD 
Age (years) 9.8 2.8 
Size of tumors (cm) 2.1 4.8 
Table 3. Frequency of benign and malignant tumors with degree of malignancy 
 Benign tumors Malignant tumors 
  I degree II degree III degree 
n 88 134 43 20.4 
Percentage (%) 29.5 63.9 20.4 15.7 
   Benign mixed tumor 12 4 
   Fibroadenoma 8 2.7 
   
Simple carcinoma   
   Carcinoma, simple 27 9.1 
   Tubopapillary carcinoma 51 17.1 
   Solid carcinoma 2 0.6 
   
Nonsimple carcinoma   
   Carcinoma in a benign mixed 
tumor 21 7 
   Complex carcinoma 99 33.2 
   
Others   
   Adenosquamous carcinoma 4 1.3 
   Carcinosarcoma 3 1 
   Myoepithelioma 2 0.6 
   Osteosarcoma 1 0.4 
 
 
Table 5. Frequencies of surgical techniques for mastectomy in 116 bitches.   
 n Percentage (%) 
Lumpectomy 14 12 
Simple mastectomy 15 13 
Regional mastectomy 39 33.5 
Unilateral mastectomy 18 15.5 
Combination of techniques 30 26% 
 
 
Table 6. Differences (mean and standard deviation: SD) in age and tumor size in 
bitches with benign or malignant tumors. 
 Age (years) Size (cm) 
 Mean SD P-value Mean SD P-value 
Benign tumors 9.1 2.8 0.007* 1.34	 1.82 0.004* 
Malignant tumors 10 2.3  2.17	 2.31  
*Significance for P < 0.05 
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